Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$81.60 USD

81.60
4,618,519

+0.23 (0.28%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up

Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.

Neogen (NEOG) Down 1.2% Since Last Earnings Report: Can It Rebound?

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.

ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx

Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

NEOG faces intense competition, which could affect the marketability and profitability of its products.

PDCO Stock Falls on Q1 Earnings & Sales Miss, Gross Margin Up Y/Y

Patterson Companies' first-quarter fiscal 2025 results reflect the negative impact of a cyberattack on its vendor, Change Healthcare.

ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition

Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Abbott's Core Businesses Thrive Despite Macroeconomic Issues

ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.

Verano Expands U.S. Cannabis Footprint With New Buyouts

This deal helps VRNOF foray into the Virginia market ahead of the Adult Use Program launch and will deepen the company's footprint in Arizona cannabis market.

Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes

PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.

Quest Diagnostics Expands in North America With New Acquisition

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.

Reasons to Retain QIAGEN Stock in Your Portfolio Now

Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.

MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition

McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.

HAE vs. BSX: Which Stock Is the Better Value Option?

HAE vs. BSX: Which Stock Is the Better Value Option?

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.

Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.